scout
Opinion|Videos|October 10, 2024

KEYNOTE-811: Latest Updates From ESMO 2024

Panelists discuss how KEYNOTE-811's study design and key findings presented at the European Society for Medical Oncology (ESMO) Congress 2024 demonstrate the potential impact of pembrolizumab plus trastuzumab and chemotherapy in HER2-positive gastric cancer treatment.

Newsletter

Stay up to date on practice-changing data in community practice.


Latest CME